Literature DB >> 19647016

A broad-range of recombination cloning vectors in mycobacteria.

Jim Sun1, Alice Lau, Xuetao Wang, Ting-Yu Angela Liao, Amina Zoubeidi, Zakaria Hmama.   

Abstract

The increased incidence of tuberculosis (TB) gave impetus for the increased interest in the study of mycobacterial genetics, which culminated in the publication of the full genome sequence of many mycobacterial strains. Since then, many genes and open reading frames of unknown function have been described and the expression of their encoded proteins is critical toward understanding the pathogenesis of TB and developing therapeutic and preventive strategies. Therefore there is an increased need for highly efficient methods for cloning of mycobacterial genes, as the limited cloning flexibility of current Escherichia coli-mycobacteria shuttle vectors remains a frequent impediment in genetic manipulation of mycobacteria. In order to overcome this limitation, we have converted representative extrachromosomal and integrative vectors into multiple destination mycobacterial vectors for one-step and restriction enzyme-free recombination cloning methodology that uses in vitro site-specific recombination. We provide several examples that highlight the potential of recombination cloning for gene expression in slow and fast-growing mycobacteria. Thus, a gene of interest can be transferred by simple recombination into our mycobacterial destination vectors, which serve a multitude of functional genomic studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19647016     DOI: 10.1016/j.plasmid.2009.07.003

Source DB:  PubMed          Journal:  Plasmid        ISSN: 0147-619X            Impact factor:   3.466


  8 in total

1.  System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis.

Authors:  Xingji Zheng; Yossef Av-Gay
Journal:  J Vis Exp       Date:  2017-04-05       Impact factor: 1.355

2.  Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.

Authors:  Santiago Ramón-García; Carol Ng; Hilary Anderson; Joseph D Chao; Xingji Zheng; Tom Pfeifer; Yossef Av-Gay; Michel Roberge; Charles J Thompson
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

3.  Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System.

Authors:  Ting-Yu Angela Liao; Alice Lau; Joseph Sunil; Vesa Hytönen; Zakaria Hmama
Journal:  J Vis Exp       Date:  2018-01-31       Impact factor: 1.355

4.  Improving the Immunogenicity of the Mycobacterium bovis BCG Vaccine by Non-Genetic Bacterial Surface Decoration Using the Avidin-Biotin System.

Authors:  Ting-Yu Angela Liao; Alice Lau; Sunil Joseph; Vesa Hytönen; Zakaria Hmama
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

5.  Mycobacterium tuberculosis exploits the PPM1A signaling pathway to block host macrophage apoptosis.

Authors:  Kaitlyn Schaaf; Samuel R Smith; Alexandra Duverger; Frederic Wagner; Frank Wolschendorf; Andrew O Westfall; Olaf Kutsch; Jim Sun
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

6.  Protein Kinase R Restricts the Intracellular Survival of Mycobacterium tuberculosis by Promoting Selective Autophagy.

Authors:  Robin Smyth; Stefania Berton; Nusrah Rajabalee; Therese Chan; Jim Sun
Journal:  Front Microbiol       Date:  2021-01-22       Impact factor: 5.640

7.  Efficient Synthesis of Benzothiazinone Analogues with Activity against Intracellular Mycobacterium tuberculosis.

Authors:  Adrian Richter; Gagandeep Narula; Ines Rudolph; Rüdiger W Seidel; Christoph Wagner; Yossef Av-Gay; Peter Imming
Journal:  ChemMedChem       Date:  2021-12-23       Impact factor: 3.540

8.  Mycobacterium tuberculosis nucleoside diphosphate kinase inactivates small GTPases leading to evasion of innate immunity.

Authors:  Jim Sun; Vijender Singh; Alice Lau; Richard W Stokes; Andrés Obregón-Henao; Ian M Orme; Dennis Wong; Yossef Av-Gay; Zakaria Hmama
Journal:  PLoS Pathog       Date:  2013-07-18       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.